Kuo Yong-Fang, Westra Jordan, Harvey Edythe P, Raji Mukaila A
Department of Biostatistics and Data Science, School of Public and Population Health, University of Texas Medical Branch, Galveston, Texas; Office of Biostatistics, University of Texas Medical Branch, Galveston, Texas; Department of Internal Medicine-Geriatric Medicine Division, John Sealy School of Medicine, University of Texas Medical Branch, Galveston, Texas; Sealy Center on Aging, University of Texas Medical Branch, Galveston, Texas.
Department of Biostatistics and Data Science, School of Public and Population Health, University of Texas Medical Branch, Galveston, Texas; Office of Biostatistics, University of Texas Medical Branch, Galveston, Texas.
Am J Prev Med. 2025 May;68(5):1015-1021. doi: 10.1016/j.amepre.2025.01.019. Epub 2025 Jan 30.
The American population diagnosed with opioid use disorder is growing, particularly those aged ≥65 years. Less than 30% of opioid use disorder patients receive medication for opioid use disorder, and even fewer older adults.
Using 20% national Medicare data, beneficiaries aged over 65 years diagnosed with opioid use disorder in 2017-2022 were selected to assess the trend and types of medication for opioid use disorder use, including methadone, buprenorphine, or naltrexone. In the 2022 cohort (n=69,380), a multivariable logistic regression model was constructed to examine the factors associated with use of medication for opioid use disorder. Analyses were performed in 2024.
Use of medications for opioid use disorder among older adults increased from 4.8% in 2017 to 7.5% in 2019 and 15.0% in 2022. The larger increase coincided with implementation of a new Medicare payment policy covering methadone for opioid use disorder. About 79% of opioid use disorder patients had chronic pain and arthritis; 50% had anemia, depression, or anxiety. Males, Black patients, Hispanic patients, older patients, and rural residents had lower odds of receiving medication for opioid use disorder. Enrollees with dual coverage from Medicaid had higher odds of receiving medication for opioid use disorder. Patients with alcohol or tobacco use disorders, anxiety, depression, hypothyroidism, or liver disease were more likely to receive medication for opioid use disorder; conversely, those with non-Alzheimer's dementia, cancer, chronic kidney disease, stroke, chronic pain, or arthritis were less likely to receive medication for opioid use disorder.
The rate of medication for opioid use disorder use was low in older adults. The disparity in medication for opioid use disorder use underscores the need for improved access to comprehensive opioid treatment programs and increased medication for opioid use disorder coverage. Additional studies of treatment patterns are also warranted.
被诊断患有阿片类药物使用障碍的美国人口正在增加,尤其是65岁及以上的人群。不到30%的阿片类药物使用障碍患者接受阿片类药物使用障碍治疗药物,而老年人接受此类药物治疗的更少。
利用20%的全国医疗保险数据,选取2017 - 2022年期间65岁以上被诊断患有阿片类药物使用障碍的受益人,以评估阿片类药物使用障碍治疗药物的使用趋势和类型,包括美沙酮、丁丙诺啡或纳曲酮。在2022年队列(n = 69380)中,构建多变量逻辑回归模型以检查与使用阿片类药物使用障碍治疗药物相关的因素。分析于2024年进行。
老年人中阿片类药物使用障碍治疗药物的使用率从2017年的4.8%增至2019年的7.5%,并在2022年达到15.0%。较大幅度的增长与一项新的医疗保险支付政策的实施相吻合,该政策涵盖了用于阿片类药物使用障碍的美沙酮。约79%的阿片类药物使用障碍患者患有慢性疼痛和关节炎;50%患有贫血、抑郁症或焦虑症。男性、黑人患者、西班牙裔患者、老年患者和农村居民接受阿片类药物使用障碍治疗药物的几率较低。同时享有医疗补助双重保险的参保人接受阿片类药物使用障碍治疗药物的几率较高。患有酒精或烟草使用障碍、焦虑症、抑郁症、甲状腺功能减退或肝病的患者更有可能接受阿片类药物使用障碍治疗药物;相反,患有非阿尔茨海默病性痴呆、癌症、慢性肾病、中风、慢性疼痛或关节炎的患者接受阿片类药物使用障碍治疗药物的可能性较小。
老年人中阿片类药物使用障碍治疗药物的使用率较低。阿片类药物使用障碍治疗药物使用方面的差异凸显了改善获得综合阿片类药物治疗项目的机会以及增加阿片类药物使用障碍治疗药物覆盖范围的必要性。对治疗模式进行更多研究也是必要的。